IDEAS home Printed from https://ideas.repec.org/a/plo/pone00/0164619.html
   My bibliography  Save this article

Projected Uptake of New Antiretroviral (ARV) Medicines in Adults in Low- and Middle-Income Countries: A Forecast Analysis 2015-2025

Author

Listed:
  • Aastha Gupta
  • Sandeep Juneja
  • Marco Vitoria
  • Vincent Habiyambere
  • Boniface Dongmo Nguimfack
  • Meg Doherty
  • Daniel Low-Beer

Abstract

With anti-retroviral treatment (ART) scale-up set to continue over the next few years it is of key importance that manufacturers and planners in low- and middle-income countries (LMICs) hardest hit by the HIV/AIDS pandemic are able to anticipate and respond to future changes to treatment regimens, generics pipeline and demand, in order to secure continued access to all ARV medicines required. We did a forecast analysis, using secondary WHO and UNAIDS data sources, to estimate the number of people living with HIV (PLHIV) and the market share and demand for a range of new and existing ARV drugs in LMICs up to 2025. UNAIDS estimates 24.7 million person-years of ART in 2020 and 28.5 million person-years of ART in 2025 (24.3 million on first-line treatment, 3.5 million on second-line treatment, and 0.6 million on third-line treatment). Our analysis showed that TAF and DTG will be major players in the ART regimen by 2025, with 8 million and 15 million patients using these ARVs respectively. However, as safety and efficacy of dolutegravir (DTG) and tenofovir alafenamide (TAF) during pregnancy and among TB/HIV co-infected patients using rifampicin is still under debate, and ART scale-up is predicted to increase considerably, there also remains a clear need for continuous supplies of existing ARVs including TDF and EFV, which 16 million and 10 million patients—respectively—are predicted to be using in 2025. It will be important to ensure that the existing capacities of generics manufacturers, which are geared towards ARVs of higher doses (such as TDF 300mg and EFV 600mg), will not be adversely impacted due to the introduction of lower dose ARVs such as TAF 25mg and DTG 50mg. With increased access to viral load testing, more patients would be using protease inhibitors containing regimens in second-line, with 1 million patients on LPV/r and 2.3 million on ATV/r by 2025. However, it will remain important to continue monitoring the evolution of ARV market in LMICs to guarantee the availability of these medicines.

Suggested Citation

  • Aastha Gupta & Sandeep Juneja & Marco Vitoria & Vincent Habiyambere & Boniface Dongmo Nguimfack & Meg Doherty & Daniel Low-Beer, 2016. "Projected Uptake of New Antiretroviral (ARV) Medicines in Adults in Low- and Middle-Income Countries: A Forecast Analysis 2015-2025," PLOS ONE, Public Library of Science, vol. 11(10), pages 1-18, October.
    • Handle: RePEc:plo:pone00:0164619
    DOI: 10.1371/journal.pone.0164619
    as

    Download full text from publisher

    File URL: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0164619
    Download Restriction: no
    File URL: https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0164619&type=printable
    Download Restriction: no
    File URL: https://libkey.io/10.1371/journal.pone.0164619?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Linda Campbell & Caroline Masquillier & Estrelle Thunnissen & Esther Ariyo & Hanani Tabana & Neo Sematlane & Anton Delport & Lorraine Tanyaradzwa Dube & Lucia Knight & Tair Kasztan Flechner & Edwin Wo, 2020. "Social and Structural Determinants of Household Support for ART Adherence in Low- and Middle-Income Countries: A Systematic Review," IJERPH, MDPI, vol. 17(11), pages 1-28, May.
    2. V Habiyambere & B Dongmo Nguimfack & L Vojnov & N Ford & J Stover & L Hasek & P Maggiore & D Low-Beer & M Pérez Gonzàlez & D Edgil & J Williams & J Kuritsky & S Hargreaves & T NeSmith, 2018. "Forecasting the global demand for HIV monitoring and diagnostic tests: A 2016-2021 analysis," PLOS ONE, Public Library of Science, vol. 13(9), pages 1-14, September.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:plo:pone00:0164619. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: plosone (email available below). General contact details of provider: https://journals.plos.org/plosone/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.